Science
Following recent encouraging interim clinical results, hear Øystein Rekdal, CEO of Lytix Biopharma, discuss with Optimum's Nick Bastin how the company's lead candidate LTX-315 has a unique approach to killing cancer. Hosted on Acast. See acast.com/privacy for more information.